BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Study acronym: TIGOS-LS
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 8 words
    • Site details revised at 34 of 34 sites
  2. Study sites: 33 to 34v12
  3. Trial sites expanded: 30 → 33 locationsv11
  4. Study sites: 27 to 30v10
  5. Study sites: 26 to 27v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 23 to 26v8
  2. Study sites: 22 to 23v7
  3. Study sites: 21 to 22v6
  4. Study sites: 16 to 21v5
  5. Study sites: 13 to 16v4
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 13
    • Start date changed from estimate of Mar 2025 to Mar 11, 2025
    v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Trial Details
NCT Number NCT06773910
Lead Sponsor SCRI Development Innovations, LLC
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Limited Stage Small Cell Lung Cancer
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov